



# STIC Search Report

## EIC 3700

STIC Database Tracking Number: 200008

TO: Paul Prebilic  
Location: RND 6c03  
Art Unit: 3738  
Monday, October 02, 2006

Case Serial Number: 10/770403

From: Kristine Sasala  
Location: EIC 3700  
Randolph 8A18-C  
Phone: (571)272-3337

kristine.sasala@uspto.gov

### Search Notes

Attached is the completed search. I did an extensive search on the requested topic in a number of bibliographic and full-text databases as well as on the Internet. I also searched the inventors in both patent and non-patent literature and have included those results. The things I thought were significant are marked with colored flags. Please be sure to look over all the results as there may be other items of interest. I have attached the search strategies used for the searches performed.

I hope you find this search helpful. If you have a moment, please fill out the attached STIC Feedback Form. And, if there is anything I can do to refine or revise this search, please let me know.


Sincerely,  
Kris Sasala (ASRC)

Solomon, Terrance

200008

From: PAUL PREBILIC [paul.prebilib@uspto.gov]  
Sent: Tuesday, August 29, 2006 7:08 AM  
To: STIC-EIC3700  
Subject: Database Search Request, Serial Number: 10770403

Requester:  
PAUL PREBILIC (P/3738)  
Art Unit:  
GROUP ART UNIT 3738  
Employee Number:  
65450  
Office Location:  
RND 06C03  
Phone Number:  
(571)272-4758  
Mailbox Number:



Case serial number:  
10770403  
Class / Subclass(es):  
623/23.64  
Earliest Priority Filing Date:  
February 4, 2004  
Format preferred for results:  
E-mail

Search Topic Information:

Please search for a method of treating morbid obesity in a patient by reducing gastric blood flow, duodenal blood flow, mesenteric blood flow, jejunal blood flow, ileal blood flow or combinations thereof by inserting a blood flow reducing device inside or outside an artery that carries blood to the small intestine.

Special Instructions and Other Comments:

SYSTEM:OS - DIALOG OneSearch  
 File 155:MEDLINE(R) 1950-2006/Sep 28  
     (c) format only 2006 Dialog  
 File 73:EMBASE 1974-2006/Sep 28  
     (c) 2006 Elsevier B.V.  
 File 5:Biosis Previews(R) 1969-2006/Sep W4  
     (c) 2006 The Thomson Corporation  
 File 34:SciSearch(R) Cited Ref Sci 1990-2006/Sep W4  
     (c) 2006 The Thomson Corp  
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
     (c) 2006 The Thomson Corp

Set Items Description  
 --- -----

Cost is in DialUnits

?

Terminal set to DLINK

? ds

Set	Items	Description
S1	5267	AU=(MURPHY T? OR MURPHY TP?)
S2	2689	ENDOGRAFT?
S3	0	S1 AND S2
S4	5683868	VASCULAR? OR RADIOLOG? OR IMAGING OR ENDOVASCULAR?
S5	706	S1 AND S4
S6	188884	(VASCULAR? OR ENDOVASCULAR?) AND (RADIOLOG? OR IMAGING)
S7	31	S1 AND S6
S8	29	RD (unique items)

8/7/10 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2006 Elsevier B.V. All rts. reserv.

10959651 EMBASE No: 2001004585  
**Technical aspects of aortoiliac interventions**

**Murphy T.P.**

Dr. T.P. Murphy, Department of Diagnostic Imaging, Brown University  
School of Medicine, Rhode Island Hospital, 593 Eddy St., Providence, RI  
02903 United States

Techniques in Vascular and Interventional Radiology ( TECH. VASC.

INTERVENT. RADIOL. ) (United States) 2000, 3/4 (189-194)

CODEN: TVIRF ISSN: 1089-2516

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 5

Just as preparation is integral to the success of any job, so is having the proper tools. It is fruitless to attempt an interventional procedure without the proper equipment. It is impossible to predict reliably the equipment necessary to complete an intervention for every patient; a broad range of catheters and guide wires must be available. If traversal of a chronically occluded artery, or any maneuver for that matter, becomes frustrating, another tool is probably needed for the job. It is simply a matter of figuring out which one, often through trial and error. Familiarity with the physical properties associated with various angioplasty balloons and stents, in addition to catheters and guide wires, is a prerequisite of expert **vascular** intervention. There are many options to chose from, but usually there is one best option. Knowledge of pharmacology is required for procedural success. There are many pitfalls associated with stent deployment, which are discussed. (C) 2000 by W.B. Saunders Company.

8/7/11 (Item 6 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2006 Elsevier B.V. All rts. reserv.

10959650 EMBASE No: 2001004584  
**Aortoiliac interventions: Getting started**

**Murphy T.P.**

Dr. T.P. Murphy, Department of Diagnostic Imaging, Brown University  
School of Medicine, Rhode Island Hospital, 593 Eddy St, Providence, RI  
02903 United States

Techniques in Vascular and Interventional Radiology ( TECH. VASC.

INTERVENT. RADIOL. ) (United States) 2000, 3/4 (186-188)

CODEN: TVIRF ISSN: 1089-2516

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Preparation is the key to the successful completion of any job. Before performing any procedure, the operator should be intimately familiar with the patient's complaint, the natural history of the disease process, and the risks and benefits of any potential interventions relative to the patient's problem. There are several considerations regarding diagnostic arteriography that implicate subsequent interventions. In general, the common femoral artery is the optimal access route for arteriography and

intervention. Occasionally, ipsilateral femoral access facilitates iliac artery revascularization, and other times contralateral access is better. Bilateral femoral access is often required. Accessing a common femoral artery without a pulse is often necessary and can usually be achieved without much difficulty. If the external iliac artery is occluded ipsilateral to the accessed femoral artery, then specialized equipment is required to permit the exchange of the access needle and traversal of the occluded iliac artery. (C) 2000 by W.B. Saunders Company.

8/7/14 (Item 9 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

07772383 EMBASE No: 1999255084

Endovascular **graft-related iliac artery infection**

Sheeran S.R.; Gestring M.L.; **Murphy T.P.** ; Slaiby J.M.

Dr. T.P. Murphy, Div. of Vasc./Interventional Radiol., Rhode Island Hospital, Brown University School of Medicine, 593 Eddy St., Providence, RI 02903 United States

Journal of Vascular and Interventional Radiology ( J. VASC. INTERVENT. RADIOL. ) (United States) 1999, 10/7 (877-882)

CODEN: JVIRE ISSN: 1051-0443

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 21

8/7/21 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0013121474 BIOSIS NO.: 200100293313

**Traumatic thoracic aortic rupture: Treatment with endovascular graft in the acute setting**

AUTHOR: Ahn Sun Ho; Cutry Anthony; **Murphy Timothy P** (Reprint); Slaiby Jeffrey M

AUTHOR ADDRESS: Department of Radiology, 593 Eddy Street, Providence, RI, 02903, USA\*\*USA

JOURNAL: Journal of Trauma Injury Infection and Critical Care 50 (5): p 949-951 May, 2001 2001

MEDIUM: print

ISSN: 1079-6061

DOCUMENT TYPE: Article

RECORD TYPE: Citation

LANGUAGE: English

# Untitled

Set	Items	Description
S1	35230980	METHOD? ? OR PROCEDURE? ? OR PROCESS OR TECHNIQUE? ? OR D-EVICE? ?
S2	17134465	(METHOD? ? OR PROCEDURE? ? OR PROCESS OR TECHNIQUE? ? OR - DEVICE? ?)/TI,DE
S3	17333300	PRODUC??? OR INDUC??? OR CREAT???
S4	3610606	(INHIBIT? OR REDUC? OR DECREAS? OR DIMINISH? OR LESSEN? OR RESTRICT? OR RETARD OR HINDER? OR LIMIT?)/TI
S5	2601376	(BLOOD? OR ARTER? OR VASCULA? OR ENDOVASCULAR)/TI
S6	2415413	GASTRIC OR GASTRODUOD? OR DUODEN? OR MESENTER? OR JEJUNO? OR JEJUN?? OR ILE?? OR ILEO? OR INTESTIN?
S7	37350	S5(3N)S6
S8	68198	S2(3N)S4
S9	39387	S4(2N)S5
S10	108896	S2(3N)S3
S11	0	S7(5N)S8(5N)S9
S12	0	S7 AND S8 AND S9
S13	630839	S1(3N)S3
S14	49496	S4(3N)S5
S15	15	S13(S)S14
S16	7	RD (unique items)
S17	0	(S8(S)S14) AND S7
S18	2184	S4(5N)S6(5N)S5
S19	348	S18 AND S1
S20	3	S18(10N)S1
S21	3	RD (unique items)
? s	s18(s)s1	
S22	3	S18(S)S1
S23	30	S18 AND OBES????
S24	12	RD (unique items)

SYSTEM:OS - DIALOG OneSearch  
File 155:MEDLINE(R) 1950-2006/Sep 28  
(c) format only 2006 Dialog  
File 5:Biosis Previews(R) 1969-2006/Sep W4  
(c) 2006 The Thomson Corporation  
File 34:SciSearch(R) Cited Ref Sci 1990-2006/Sep W4  
(c) 2006 The Thomson Corp  
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
(c) 2006 The Thomson Corp  
File 73:EMBASE 1974-2006/Sep 29  
(c) 2006 Elsevier B.V.  
File 74:Int.Pharm.Abs 1970-2006/Aug B1  
(c) 2006 The Thomson Corporation  
File 2:INSPEC 1898-2006/Sep W3  
(c) 2006 Institution of Electrical Engineers  
File 6:NTIS 1964-2006/Sep W3  
(c) 2006 NTIS, Intl Cpyrght All Rights Res  
File 8:Ei Compendex(R) 1970-2006/Sep W3  
(c) 2006 Elsevier Eng. Info. Inc.  
File 35:Dissertation Abs Online 1861-2006/Sep  
(c) 2006 ProQuest Info&Learning  
File 65:Inside Conferences 1993-2006/Sep 28  
(c) 2006 BLDSC all rts. reserv.  
File 94:JICST-EPlus 1985-2006/Jun W3  
(c)2006 Japan Science and Tech Corp(JST)  
File 98:General Sci Abs 1984-2006/Sep  
(c) 2006 The HW Wilson Co.  
File 99:Wilson Appl. Sci & Tech Abs 1983-2006/Jul  
(c) 2006 The HW Wilson Co.  
File 144:Pascal 1973-2006/Sep W1  
(c) 2006 INIST/CNRS  
File 23:CSA Technology Research Database 1963-2006/Sep  
(c) 2006 CSA.

21/5/1 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2006 Dialog. All rts. reserv.

19311272 PMID: 15634399

[The clinical study on application of using a novel blockade technique for gastric cancer to decrease blood -borne metastasis of cancer cells]

Huang Guang-Jian; Zhang Qun-Hua; Zhang Yan-Ling; Gan Jun; Chen Yu-Ming; Guan Ming; Ni Quan-Xing

Department of Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China.

Zhonghua wai ke za zhi Chinese journal of surgery (China) Nov 22 2004, 42 (22) p1345-8, ISSN 0529-5815--Print Journal Code: 0153611

Publishing Model Print

Document type: Journal Article

Languages: CHINESE

Main Citation Owner: NLM

Record type: In Process

Subfile: INDEX MEDICUS

OBJECTIVE: To evaluate the effect of a novel blockade technique for gastric cancer on blood-borne metastasis of gastric cancer cells to portal vein. METHODS: Twenty-three cases of gastric cancer were divided into routine operation group (8 cases intraoperatively without blockade technique) and blockade group (15 cases with blockade technique). Blood samples from portal vein pre- and intraoperatively, as well as gastroepiploic vein limited within the blockade area were obtained to detect CK19 mRNA expression by using RT-PCR technique. RESULTS: Before the dissection of gastric lesion, the overall positive rate of CK19 mRNA expression in portal vein blood is 34.7% (9/23), including 37.5% (3/8) in routine operation group and 33.3% (5/15) in blockade group. While the course of tumor resection, those positive rates were 87.5% (7/8) in routine operation group and 6.7% (1/15) in blockade group respectively ( $P < 0.05$ ). CK19 mRNA expression in the right gastroepiploic venous blood limited within the blocking area was all positive in 15 cases of blockade group. CONCLUSION: This blockade technique can be used effectively to block the intraoperative spread of gastric cancer



24/5/8 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0002311642 BIOSIS NO.: 197815029129

**CARDIO VASCULAR EFFECTS OF WEIGHT REDUCTION AFTER INTESTINAL SHUNT  
OPERATION FOR OBESITY**

AUTHOR: FREYSCHUSS U; BACKMAN L; HALLBERG D; MELCHER A

JOURNAL: British Heart Journal 40 (4): p462 1978

ISSN: 0007-0769

DOCUMENT TYPE: Article

RECORD TYPE: Citation

LANGUAGE: Unspecified

DESCRIPTORS: ABSTRACT JEJUNO ILEOSTOMY

**DESCRIPTORS:**

MAJOR CONCEPTS: Cardiovascular Medicine--Human Medicine, Medical Sciences  
; Digestive System--Ingestion and Assimilation; Nutrition

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata,  
Animalia

COMMON TAXONOMIC TERMS: Animals; Chordates; Humans; Mammals; Primates;  
Vertebrates

**CONCEPT CODES:**

11105 Anatomy and Histology - Surgery

12002 Physiology - General

12512 Pathology - Therapy

13203 Nutrition - Malnutrition and obesity

14001 Digestive system - General and methods

14506 Cardiovascular system - Heart pathology

14508 Cardiovascular system - Blood vessel pathology

**BIOSYSTEMATIC CODES:**

86215 Hominidae

Set	Items	Description
S1	10607043	(BLOOD? OR ARTER? OR VASCULA? OR ENDOVASCULAR)/TI,DE
S2	4020151	CIRCULAT???
S3	2438687	GASTRIC OR GASTRODUOD? OR DUODEN? OR MESENTER? OR JEJUNO? OR JEJUN?? OR ILE?? OR ILEO? OR INTESTIN? OR SPLANCHN?
S4	23972020	INHIBIT? OR REDUC? OR DECREAS? OR DIMINISH? OR LESSEN? OR - RESTRICT? OR RETARD OR HINDER? OR LIMIT? OR CONSTRICT???
S5	2469	BLOODFLOW?
S6	6300276	FLOW OR SUPPLY???
S7	134779	S1:S2(5N)S3
S8	356057	S4(5N)S5:S6
S9	346	S8(S)THERAPEUTIC()USE
S10	4	S9 AND S7
S11	1508	S7(S)S8
S12	64522	S4(S)THERAPEUTIC()USE
S13	4	S11 AND S12
S14	2438687	S3/BS
S15	625492	ISCHEMIA/TU
S16	37159	S14 AND S15
S17	25936	S14(S)S15
S18	1062559	S3/TI
S19	14566	S18 AND S17
S20	512	S5/TI
S21	3635185	S4/TI
S22	6125	S4 AND S19
S23	13	(S1 AND S2 AND S3 AND S4 AND (S5:S6))/TI
S24	8	RD (unique items)
File	155:MEDLINE(R)	1950-2006/Sep 28 (c) format only 2006 Dialog
File	5:Biosis Previews(R)	1969-2006/Sep W4 (c) 2006 The Thomson Corporation
File	34:SciSearch(R)	Cited Ref Sci 1990-2006/Sep W4 (c) 2006 The Thomson Corp
File	434:SciSearch(R)	Cited Ref Sci 1974-1989/Dec (c) 2006 The Thomson Corp
File	73:EMBASE	1974-2006/Sep 29 (c) 2006 Elsevier B.V.
File	74:Int.Pharm.Abs	1970-2006/Aug B1 (c) 2006 The Thomson Corporation
File	2:INSPEC	1898-2006/Sep W3 (c) 2006 Institution of Electrical Engineers
File	6:NTIS	1964-2006/Sep W3 (c) 2006 NTIS, Intl Cpyrght All Rights Res
File	8:Ei Compendex(R)	1970-2006/Sep W3 (c) 2006 Elsevier Eng. Info. Inc.
File	35:Dissertation Abs Online	1861-2006/Sep (c) 2006 ProQuest Info&Learning
File	65:Inside Conferences	1993-2006/Sep 29 (c) 2006 BLDSC all rts. reserv.
File	94:JICST-EPlus	1985-2006/Jun W3 (c)2006 Japan Science and Tech Corp(JST)
File	98:General Sci Abs	1984-2006/Sep (c) 2006 The HW Wilson Co.
File	99:Wilson Appl. Sci & Tech Abs	1983-2006/Jul (c) 2006 The HW Wilson Co.
File	144:Pascal	1973-2006/Sep W1 (c) 2006 INIST/CNRS
File	23:CSA Technology Research Database	1963-2006/Sep (c) 2006 CSA.

24/5/6 (Item 3 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0001898793 BIOSIS NO.: 197661064932

**CONTINUOUS BLOOD FLOW AS A MANIFESTATION OF REDUCED CIRCULATION IN  
INTESTINAL INTRA MURAL VESSELS**

AUTHOR: SIGAL Z M

JOURNAL: Patologicheskaya Fiziologiya i Eksperimental'naya Terapiya (4): p  
74-77 1975

ISSN: 0031-2991

DOCUMENT TYPE: Article

RECORD TYPE: Citation

LANGUAGE: Unspecified

DESCRIPTORS: DOG BLOODLESS METHOD LIGATION

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Blood and  
Lymphatics--Transport and Circulation; Cardiovascular System--Transport  
and Circulation; Digestive System--Ingestion and Assimilation

BIOSYSTEMATIC NAMES: Canidae--Carnivora, Mammalia, Vertebrata, Chordata,  
Animalia

COMMON TAXONOMIC TERMS: Animals; Carnivores; Chordates; Mammals; Nonhuman  
Vertebrates; Nonhuman Mammals; Vertebrates

CONCEPT CODES:

10502 Biophysics - General

11104 Anatomy and Histology - Experimental anatomy

12100 Movement

14001 Digestive system - General and methods

14004 Digestive system - Physiology and biochemistry

14006 Digestive system - Pathology

14501 Cardiovascular system - General and methods

14504 Cardiovascular system - Physiology and biochemistry

14508 Cardiovascular system - Blood vessel pathology

15002 Blood - Blood and lymph studies

BIOSYSTEMATIC CODES:

85765 Canidae

24/5/7 (Item 4 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts.. reserv.

0000177003 BIOSIS NO.: 196905080155

**CIRCULATORY RESPONSES TO ACUTE REDUCTION OF SUPERIOR MESENTERIC  
ARTERIAL FLOW**

AUTHOR: BOLEY S J; TREIBER W; WINSLOW P R; GLIEDMAN M L; VEITH F J

JOURNAL: Physiologist 12 (3): p180 1969

ISSN: 0031-9376

DOCUMENT TYPE: Article

RECORD TYPE: Citation

LANGUAGE: Unspecified

DESCRIPTORS: ABSTRACT DOG

DESCRIPTORS:

MAJOR CONCEPTS: Cardiovascular System--Transport and Circulation

BIOSYSTEMATIC NAMES: Canidae--Carnivora, Mammalia, Vertebrata, Chordata,  
Animalia

COMMON TAXONOMIC TERMS: Animals; Carnivores; Chordates; Mammals; Nonhuman  
Vertebrates; Nonhuman Mammals; Vertebrates

CONCEPT CODES:

14504 Cardiovascular system - Physiology and biochemistry

14508 Cardiovascular system - Blood vessel pathology

BIOSYSTEMATIC CODES:  
85765 Canidae

24/5/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

04030355 PMID: 1187231

**[Continuous blood flow as a manifestation of reduced blood circulation in the intramural vessels of the intestine]**

Nepreryvnyi krovotok kak proiavlenie redutsirovannogo krovoobrashcheniia v intramural'nykh sosudakh kishki

Sigal Z M

Patologicheskaiia fiziologiia i eksperimental'naia terapiia (USSR)  
Jul-Aug 1975, (4) p74-7, ISSN 0031-2991--Print Journal Code: 0376421

Publishing Model Print

Document type: Journal Article ; English Abstract

Languages: RUSSIAN

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

Descriptors: \*Intestines--blood supply--BS; \*Regional Blood Flow; Animals  
; Blood Pressure; Dogs; English Abstract; Ligation

Record Date Created: 19760123

Record Date Completed: 19760123

24/5/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

01241317 PMID: 13683150

**Distribution of splanchnic and peripheral blood flow during acute reduction in circulatory rate: studies during total body perfusion.**

ANDERSEN M N; HAMBRAEUS G; ALFANO G A; SCHENK W G

Annals of surgery (Not Available) Apr 1961, 153 p477-82, ISSN  
0003-4932--Print Journal Code: 0372354

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: OLDMEDLINE; Completed

Subfile: OLDMEDLINE

Descriptors: \*Blood Circulation--physiology--PH; \*Heart, Artificial

Identifiers: \*BLOOD CIRCULATION/physiology; \*HEART, MECHANICAL

Record Date Created: 19611201

Record Date Completed: 19981101

Set	Items	Description
S1	497349	BLOOD? OR ARTER? OR VASCULA? OR ENDOVASCULAR OR CIRCULATORY
S2	71066	GASTRIC OR GASTRODUOD? OR DUODEN? OR MESENTER? OR JEJUNO? OR JEJUN?? OR ILE?? OR ILEO? OR INTESTIN? OR SPLANCHN?
S3	221	BLOODFLOW?
S4	6112295	FLOW OR SUPPLY??? OR SUPPLI???
S5	7889757	INHIBIT? OR REDUC? OR DECREAS? OR DIMINISH? OR LESSEN? OR - RESTRICT? OR RETARD OR HINDER? OR LIMIT? OR CONSTRICT???
S6	18192574	PRODUC??? OR INDUC??? OR CREAT???
S7	886	S1(2N)S2
S8	118053	S5(2N)(S1OR S3 OR S4)
S9	37316	S1(5N)S5
S10	13	S7(S)S8(S)S9
S11	13	RD (unique items)
S12	1613	S1(5N)S2
S13	209088	S5(5N)(S1OR S3 OR S4)
S14	59	S12(S)S13(S)S9
S15	46	RD (unique items)
File 16:	Gale Group PROMT(R) 1990-2006/Sep 28 (c) 2006 The Gale Group	
File 160:	Gale Group PROMT(R) 1972-1989 (c) 1999 The Gale Group	
File 148:	Gale Group Trade & Industry DB 1976-2006/Sep 29 (c)2006 The Gale Group	
File 621:	Gale Group New Prod.Annou.(R) 1985-2006/Sep 28 (c) 2006 The Gale Group	
File 9:	Business & Industry(R) Jul/1994-2006/Sep 28 (c) 2006 The Gale Group	

15/3,K/2 (Item 2 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2006 The Gale Group. All rts. reserv.

12648359 Supplier Number: 137910699 (USE FORMAT 7 FOR FULLTEXT)  
**Cook Offers First Fenestrated Endograft With CE Mark Approval For Complex Aortic Aneurysms.**  
Business Wire, pNA  
Oct 25, 2005  
Language: English Record Type: Fulltext  
Document Type: Newswire; Trade  
Word Count: 714

... stent-graft to treat aortic and aortoiliac aneurysms extending close to the renal and superior **mesenteric arteries**, which are then stented to **reduce** the risk of **restricting** or blocking critical **blood flow** to the kidneys and bowel. Each fenestrated device is custom-made to suit individual patients...

15/3,K/20 (Item 3 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2006 The Gale Group. All rts. reserv.

15375017 SUPPLIER NUMBER: 96058113 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Acute mesenteric ischemia. (Case in Point).**  
Schubert, Steven R.  
Consultant, 42, 14, 1796(3)  
Dec, 2002  
ISSN: 0010-7069 LANGUAGE: English RECORD TYPE: Fulltext  
WORD COUNT: 1414 LINE COUNT: 00136

... mesenteric artery causes ischemia in the small intestine and the right half of the colon. **Reduced blood flow** from the inferior **mesenteric artery** leads to ischemia of the distal transverse colon and proximal rectum. Possible sequelae range from...

15/3,K/27 (Item 10 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2006 The Gale Group. All rts. reserv.

07293760 SUPPLIER NUMBER: 15441934 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Management of oesophageal varices. (review article)**  
Bornman, P.C.; Krige, J.E.J.; Terblanche, J.  
Lancet, v343, n8905, p1079(6)  
April 30, 1994  
ISSN: 0099-5355 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 5598 LINE COUNT: 00482

... not cause systemic vasoconstriction. Somatostatin acts on the smooth muscle of splanchnic vessels with a **reduction** in **splanchnic** and hepatic **blood flow**. Although the **reduction** of wedged hepatic, portal, and intravariceal pressures appears to be modest in stable cirrhotics, azygous...

15/3,K/29 (Item 12 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2006 The Gale Group. All rts. reserv.

06748682      SUPPLIER NUMBER: 14425718      (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Octreotide infusion or emergency sclerotherapy for variceal haemorrhage.**  
Sung, Joseph J.Y.; Chung, S.C. Sydney; Lai Chi-Wai; Chan, Francis K.L.;  
Leung, Joseph W.C.; Yung Man-Yee; Kassianides, Chris; Li, Arthur K.C.  
Lancet, v342, n8872, p637(5)  
Sept 11, 1993  
ISSN: 0099-5355      LANGUAGE: ENGLISH      RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 3006      LINE COUNT: 00249

... Even with the best combination - terlipressin and nitroglycerin -  
the results are conflicting.[3] Native somatostatin **reduces splanchnic  
blood flow**, [4] and azygous **blood flow**, a measurement of collateral  
circulation including variceal flow that falls with an infusion of...

15/3,K/40      (Item 23 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2006 The Gale Group. All rts. reserv.

03939528      SUPPLIER NUMBER: 07731657      (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Acute mesenteric ischemia: what's new in GI ischemic disorders? (part 1)**  
Brandt, Lawrence J.; Dickstein, George  
Consultant, v29, n6, p107(6)  
June, 1989  
ISSN: 0010-7069      LANGUAGE: ENGLISH      RECORD TYPE: FULLTEXT  
WORD COUNT: 4114      LINE COUNT: 00376

... In experimental models of acute mesenteric ischemia, tonometry has  
made correct and reproducible determinations of **diminished intestinal  
blood flow** .[24] While promising, the utility of ...Also, theoretically,  
the increased intraluminal pressure caused by the distention that  
accompanies these procedures may **decrease** the already compromised  
**intestinal blood flow** .

Hydrogen gas clearance. Hydrogen gas clearance is a well documented  
endoscopic technique used to assess...

...predicted by reflectance spectrophotometry and laser Doppler methods,  
displayed a linear correlation with the percentage **decreasing** in superior  
**mesenteric artery flow** , tonometry showed a linear **decrease** only  
when **arterial** occlusion was greater than 25%.

Endoscopic reflectance spectrophotometry is discussed in detail in  
part 2...



Set	Items	Description
S1	225304	BLOOD? OR ARTER? OR VASCULA? OR ENDOVASCULAR OR CIRCULATORT
S2	9330	CIRCULATORY
S3	231268	S1:S2
S4	51349	GASTRIC OR GASTRODUOD? OR DUODEN? OR MESENTER? OR JEJUNO? OR JEJUN?? OR ILE?? OR ILEO? OR INTESTIN? OR SPLANCHN?
S5	67	BLOODFLOW?
S6	3007344	FLOW OR SUPPLY??? OR SUPPLI???
S7	4951221	INHIBIT? OR REDUC? OR DECREAS? OR DIMINISH? OR LESSEN? OR - RESTRICT? OR RETARD OR HINDER? OR LIMIT? OR CONSTRICT???
S8	3825589	PRODUC??? OR INDUC??? OR CREAT???
S9	2315	S3(5N)S4
S10	164432	S7(5N) (S3 OR S5 OR S6)
S11	378	S9(S)S10
S12	136747	S7(5N)S8
S13	30	S11(S)S12
S14	1218	S3(2N)S4
S15	95050	S7(2N) (S3 OR S5 OR S6)
S16	25088	S3(5N)S7
S17	123	S14(S)S15(S)S16

File 347:JAPIO Dec 1976-2005/Dec(Updated 060404)  
(c) 2006 JPO & JAPIO

File 350:Derwent WPIX 1963-2006/UD=200661  
(c) 2006 The Thomson Corporation

17/5/9 (Item 9 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2006 Dialog. All rts. reserv.

21677217 PMID: 16915109

**Membrane microdialysis: Evaluation of a new method to assess splanchnic tissue metabolism.**

Knuesel Rafael; Takala Jukka; Brander Lukas; Haenggi Matthias; Bracht Hendrik; Porta Francesca; Jakob Stephan M  
Clinic for Intensive Care Medicine, University Hospital of Bern (Inselspital), Bern, Switzerland.

Critical care medicine (United States) Oct 2006, 34 (10) p2638-45,  
ISSN 0090-3493--Print Journal Code: 0355501

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Process

Subfile: AIM; INDEX MEDICUS

**OBJECTIVE:** Measuring peritoneal lactate concentrations could be useful for detecting **splanchnic** hypoperfusion. The aims of this study were to evaluate the properties of a new membrane-based microdialyzer in vitro and to assess the ability of the dialyzer to detect a clinically relevant decrease in **splanchnic** blood flow in vivo. **DESIGN:** A membrane-based microdialyzer was first validated in vitro. The same device was tested afterward in a randomized, controlled animal experiment. **SETTING:** University experimental research laboratory. **SUBJECTS:** Twenty-four Landrace pigs of both genders. **INTERVENTIONS:** In vitro: Membrane microdialyzers were kept in warmed sodium lactate baths with lactate concentrations between 2 and 8 mmol/L for 10-120 mins, and microdialysis lactate concentrations were measured repeatedly (210 measurements). In vivo: An extracorporeal shunt with blood reservoir and roller pump was inserted between the proximal and distal abdominal aorta, and a microdialyzer was inserted intraperitoneally. In 12 animals, total **splanchnic** blood flow (measured by transit time ultrasound) was reduced by a median 43% (range, 13% to 72%) by activating the shunt; 12 animals served as controls. **MEASUREMENTS AND MAIN RESULTS:** In vitro: The fractional lactate recovery was 0.59 (0.32-0.83) after 60 mins and 0.82 (0.71-0.87) after 90 mins, with no further increase thereafter. At 60 and 90 mins, the fractional recovery was independent of the lactate concentration. In vivo: Abdominal blood flow reduction resulted in an increase in peritoneal microdialysis lactate concentration from 1.7 (0.3-3.8) mmol/L to 2.8 (1.3-6.2) mmol/L ( $p = .006$ ). At the same time, **mesenteric** venous-arterial lactate gradient increased from 0.1 (-0.2-0.8) mmol/L to 0.3 (-0.3 -1.8) mmol/L ( $p = .032$ ), and **mesenteric** venous-arterial  $P_{CO_2}$  gradients increased from 12 (8-19) torr to 21 (11-54) torr ( $p = .005$ ). **CONCLUSIONS:** Peritoneal membrane microdialysis provides a method for the assessment of **splanchnic ischemia**, with potential for clinical application.

Record Date Created: 20060919

17/5/15 (Item 14 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0015239652 - Drawing available

WPI ACC NO: 2005-589724/200560

XRAM Acc No: C2005-177900

XRPX Acc No: N2005-483633

**Treatment of morbid obesity in patient, by reducing gastric blood flow, duodenal blood flow, mesenteric blood flow, jejunal blood flow, and/or ileal blood flow in patient**

Patent Assignee: MURPHY T P (MURP-I)

Inventor: MURPHY T P

**Patent Family** (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
US 20050171556	A1	20050804	US 2004770403	A	20040204	200560 B

Priority Applications (no., kind, date): US 2004770403 A 20040204

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
US 20050171556	A1	EN	9	4	

#### Alerting Abstract US A1

NOVELTY - Treatment of morbid obesity in a patient comprises **reducing gastric blood flow, duodenal blood flow, mesenteric blood flow, jejunal blood flow, and/or ileal blood flow** in the patient.

DESCRIPTION - INDEPENDENT CLAIMS are also included for:

- 1.an endograft (100) comprising a hollow first portion configured and arranged to be self-expanding, and a hollow second portion attached to the first portion configured and arranged to be expandable and to maintain a shape; and
- 2.a system comprising an endograft, and a hollow elongated sheath having a lumen and a distal end, the endograft positioned in the sheath lumen at the sheath distal end.

USE - For treating morbid obesity in a patient.

ADVANTAGE - The inventive method is safe and effective.

DESCRIPTION OF DRAWINGS - The figure schematically illustrates an endograft device.

- 100 Endograft device
- 102 First end section
- 104 Second end section
- 106 Central section
- 118 Lumen

**Title Terms/Index Terms/Additional Words:** TREAT; OBESITY; PATIENT; REDUCE; GASTRIC; BLOOD; FLOW; DUODENAL; MESENTERY

#### Class Codes

International Classification (Main): A61B-017/122

(Additional/Secondary): A61F-002/06

US Classification, Issued: 606108000, 623001310, 128898000, 606158000

File Segment: CPI; EngPI

DWPI Class: A96; D22; P31; P32

Manual Codes (CPI/A-M): A04-E08; A12-V03D; D09-C

17/5/18 (Item 17 from file: 350)  
DIALOG(R)File 350:Derwent WPIX  
(c) 2006 The Thomson Corporation. All rts. reserv.

0014650549

WPI ACC NO: 2004-832568/200482

Related WPI Acc No: 2004-832551

XRAM Acc No: C2004-288994

**Method for causing constriction of arterial microvasculature e.g. striated muscle microvasculature by administration of cannabinoid receptor agonist and cyclooxygenase-2 inhibitor**

Patent Assignee: BOB M (BOBM-I); MOORE B M (MOOR-I); UNIV TENNESSEE RES  
FOUND (UYTE-N)

Inventor: MOORE B; MOORE B M

**Patent Family** (5 patents, 107 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
US 20040229928	A1	20041118	US 2003436028	A	20030512	200482 B
WO 2004100867	A2	20041125	WO 2004US11222	A	20040412	200482 E
US 6916852	B2	20050712	US 2003436028	A	20030512	200546 E
EP 1626724	A2	20060222	EP 2004760806	A	20040412	200615 E
			WO 2004US11222	A	20040412	
AU 2004238205	A1	20041125	AU 2004238205	A	20040412	200638 E

Priority Applications (no., kind, date): US 2003436028 A 20030512

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
--------	------	-----	----	-----	--------------

US 20040229928	A1	EN	11	6	
----------------	----	----	----	---	--

WO 2004100867	A2	EN			
---------------	----	----	--	--	--

National Designated States,Original: AE AG AL AM AT AU AZ BA BB BG BR BW  
BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR  
HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW  
MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR  
TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Regional Designated States,Original: AT BE BG BW CH CY CZ DE DK EA EE ES  
FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PL PT RO SD SE SI SK  
SL SZ TR TZ UG ZM ZW

EP 1626724	A2	EN			
------------	----	----	--	--	--

PCT Application WO 2004US11222

Based on OPI patent WO 2004100867

Regional Designated States,Original: AL AT BE BG CH CY CZ DE DK EE ES FI  
FR GB GR HR HU IE IT LI LT LU LV MC MK NL PL PT RO SE SI SK TR

AU 2004238205	A1	EN			
---------------	----	----	--	--	--

Based on OPI patent WO 2004100867

#### Alerting Abstract US A1

NOVELTY - A method for causing constriction of arterial microvasculature involves administration of a cannabinoid receptor agonist (a1) and a COX-2 inhibitor (b1).

ACTIVITY - Hemostatic; Vasotropic; Hypertensive; Muscular-Gen.

MECHANISM OF ACTION - Cannabinoid receptor agonist (CRA); Cyclooxygenase (COX)-2 inhibitor. The effects of a CRA on cremaster arterioles, alone and in combination with a COX-2 inhibitor were studied. CRA used was Delta8-tetrahydrocannabinol (THC) and the COX-2 inhibitor used was NS-398 (N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide). The combination of THC and NS-398 produced a pronounced and prolonged constriction of cremaster arterioles of about a 45% decrease in arteriolar diameter lasting for the entire duration of the experiment of 750 seconds. Both THC alone and THC in combination with NS-398 caused an initial mild constriction of about 15% in the arterioles. At about 30 seconds post-administration, however, the diameter of the cremaster arterioles in the mice receiving only THC returned to baseline diameter. In contrast, the diameter of the

cremaster arterioles in the mice receiving both THC and NS-398 continued to decrease.

USE - For causing constriction of arterial microvasculature e.g. striated muscle microvasculature to a vertebrate subject such as mammal e.g. human; for increasing blood pressure in a subject suffering from an acute decrease in blood pressure; for treating shock e.g. hemorrhagic shock (claimed).

ADVANTAGE - The combination provides a synergistic effect when administered to a vertebrate animal and produces a pronounced, prolonged constriction of arterial microvasculature, especially in the microvasculature of striated muscle while having a lesser effect in the **splanchnic vasculature**. (b1) counters the tendency of an administered cannabinoid receptor agonist to cause dilation of arterial musculature; and controls hypotension associated with anesthetic agents. The compounds regulate tone of small blood vessels. (a1) and (b1) are administered in lower dosage.

**Title Terms/Index Terms/Additional Words:** METHOD; CAUSE; CONSTRICT; ARTERY; STRIATED; MUSCLE; ADMINISTER; CANNABINOID; RECEPTOR; AGONIST; INHIBIT

**Class Codes**

International Classification (Main): A61K, A61K-031/164, A61K-031/365, A61K-031/415

(Additional/Secondary): A61K-031/16, A61K-031/18, A61K-031/353

International Classification (+ Attributes)

IPC + Level Value Position Status Version

A61K-0031/415 A I L B 19850101

A61K-0031/52 A I F B 19850101

US Classification, Issued: 514406000, 514454000, 514473000, 514613000, 514605000, 514627000

File Segment: CPI

DWPI Class: B05

Manual Codes (CPI/A-M): B06-A03; B07-A01; B07-D04C; B07-D08; B07-E01; B10-A08; B14-F02C; B14-F08

**17/5/19 (Item 18 from file: 350)**

DIALOG(R) File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0014650532

WPI ACC NO: 2004-832551/

Related WPI Acc No: 2004-832568

XRAM Acc No: C2004-288977

**Causing constriction of arterial microvasculature in vertebrate comprises co-administration of cannabinoid receptor agonist and cyclooxygenase-2 inhibitor**

Patent Assignee: MOORE B M (MOOR-I)

Inventor: MOORE B M

**Patent Family** (1 patents, 1 countries)

Patent			Application			
Number	Kind	Date	Number	Kind	Date	Update
US 20040229850	A1	20041118	US 2003436028	A	20030512	200482 B
			US 2004822354	A	20040412	

Priority Applications (no., kind, date): US 2003436028 A 20030512; US 2004822354 A 20040412

**Patent Details**

Number	Kind	Lan	Pg	Dwg	Filing Notes
US 20040229850	A1	EN	11	6	C-I-P of application US 2003436028

**Alerting Abstract US A1**

**NOVELTY** - Causing constriction of arterial microvasculature in a vertebrate comprises co-administration of a cannabinoid receptor agonist and cyclooxygenase-2 (COX-2) (preferably COX-1) inhibitor.

**ACTIVITY** - Hypertensive; Vasotropic; Hemostatic.

In a test, Sprague Dawley rats were injected with vehicle (200  $\mu$ l) (control animals) or a binary drug solution in the same vehicle to provide a dose of tetrahydrocannabinol (THC) (12 mg/kg) and \*\*NS-398\*\* (RTM; N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide) (2 mg/kg) (test combination). The blood pressure in rats treated with vehicle continued to drop to below 20 mm Hg 40-50 minutes following the onset of stepwise bleeding. The blood pressure in rats treated with the test combination did not drop below the blood pressure (40 mm Hg) at the time of injection of the combination of COX-2 inhibitor and cannabinoid receptor agonist. The blood pressure increased following this injection and remained elevated above this blood pressure for at least 6 hours.

**MECHANISM OF ACTION** - None given.

**USE** - Used for causing constriction of arterial microvasculature (preferably striated muscle microvasculature), increasing blood pressure and for treating a subject suffering from or at risk of developing shock e.g. hemorrhagic shock (claimed).

**ADVANTAGE** - The method increases blood pressure when a subject is suffering from an acute decrease in blood pressure. The co-administration controls hypotension associated with anesthetic agents. The combination provides a synergistic effect and produces a pronounced, prolonged constriction of arterial microvasculature, especially in the microvasculature of striated muscle, and has a preferential effect in causing constriction of arterial vasculature of striated muscle while having a lesser effect in the **splanchnic vasculature**, which results in a shunt of blood flow away from skeletal and other striated muscle, which makes a greater volume of blood available for other organs, such as vital organs like the brain and abdominal organs. The method tones the arterial microvasculature.

**Title Terms/Index Terms/Additional Words:** CAUSE; CONSTRICT; ARTERY; VERTEBRATE; COMPRISE; CO; ADMINISTER; CANNABINOID; RECEPTOR; AGONIST; INHIBIT

**Class Codes**

International Classification (Main): A61K-031/60

(Additional/Secondary): A61K-031/365, A61K-031/415

US Classification, Issued: 514165000, 514406000, 514471000

File Segment: CPI

DWPI Class: B05

Manual Codes (CPI/A-M): B07-A01; B07-D04C; B07-D08; B07-E01; B10-A08; B10-D03; B10-E04C; B14-D05C; B14-F02A; B14-F02C; B14-L06; B14-S05

17/5/27 (Item 26 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0014098996

WPI ACC NO: 2004-282770/200426

XRAM Acc No: C2004-108606

**Stable, viable probiotic compositions, useful for intestinal targeting, comprise probiotic microspheres having a core (containing probiotic bacteria, a cellulosic excipient and a disintegrant) and a gastric fluid-resistant enteric coating**

Patent Assignee: CANACURE CORP (CANA-N); GUERIN D (GUER-I); JOLY M (JOLY-I); MOSLEMY P (MOSL-I); PAQUETTE G D (PAQU-I); SIMMONS D L (SIMM-I)  
Inventor: GUERIN D; JOLY M; MOSLEMY P; PAQUETTE G D; PAQUETTE G O; SIMMONS D L

**Patent Family** (4 patents, 104 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
WO 2004022031	A2	20040318	WO 2003CA1365	A	20030908	200426 B
AU 2003266061	A1	20040329	AU 2003266061	A	20030908	200459 E
US 20050266069	A1	20051201	US 2002408348	P	20020906	200579 E
			US 2003656386	A	20030905	
AU 2003266061	A8	20051027	AU 2003266061	A	20030908	200624 E

Priority Applications (no., kind, date): US 2003656386 A 20030905; US 2002408348 P 20020906

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 2004022031	A2	EN	38	0	

National Designated States, Original: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

Regional Designated States, Original: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

AU 2003266061	A1	EN		Based on OPI patent	WO 2004022031
US 20050266069	A1	EN		Related to Provisional	US 2002408348
AU 2003266061	A8	EN		Based on OPI patent	WO 2004022031

#### Alerting Abstract WO A2

NOVELTY - Viable and stable probiotic formulation (I) for intestinal targeting comprising probiotic microspheres that comprise a core (containing one or more probiotic bacteria (A), a cellulosic excipient (B), a disintegrant (C) and one or more additives (D)) and an enteric coating (E) capable of being resistant to gastric fluids, is new.

DESCRIPTION - Viable and stable probiotic formulation (I) for intestinal targeting comprises probiotic microspheres, each having a residual moisture level of less than 5% and a water activity (aw) of 0.1-0.5 and each comprising:

- 1.a core containing one or more probiotic bacteria (A);
- 2.a cellulosic excipient (B);
- 3.a disintegrant (C);
- 4.one or more additives (D); and
- 5.an enteric coating (E) capable of being resistant to gastric fluids.

An INDEPENDENT CLAIM is also included for the preparation of (I).

ACTIVITY - Gastrointestinal-Gen.; Immunomodulator; Antimicrobial; Hypotensive; Cytostatic.

No biological data is given.

MECHANISM OF ACTION - None given.

USE - (I) is useful for intestinal targeting (claimed) e.g. modulating immune response, improving lactose intolerance symptoms, increasing resistance to infectious intestinal diseases, reducing blood pressure and helping to prevent colon cancer.

ADVANTAGE - (I) can be prepared by cost-effective processes that are capable of entrapping and stabilizing probiotics in microspheres with minimal viability loss at the end of the entire operation. (I) provide uniform microsphere compositions within a narrow size distribution range, with low residual moisture contents and aw values that contain probiotics targeted to specific regions of the intestinal tract. Additionally, (I) are stable at room temperature for greater than 18-25 months. The bioavailability of (I) was tested by exposure to simulated gastric juice. The results showed (I) to have no reduction in viable bacteria after 1 hour exposure to the simulated gastric fluids.

**Title Terms/Index Terms/Additional Words:** STABILISED; VIABLE; COMPOSITION; USEFUL; INTESTINAL; COMPRISE; MICROSPHERE; CORE; CONTAIN; BACTERIA; CELLULOSIC; EXCIPIENT; DISINTEGRATE; GASTRIC; FLUID; RESISTANCE; ENTERAL; COATING

**Class Codes**

International Classification (Main): A23L-001/30; A61K-045/00, A61K-009/00  
(Additional/Secondary): A61K-009/48, A61K-009/50  
US Classification, Issued: 424451000, 424093450

File Segment: CPI

DWPI Class: A96; B04; D16

Manual Codes (CPI/A-M): A03-A05; A12-V01; B04-C02; B04-C03; B04-F10;  
B10-G02; B12-M11E; B14-A01; B14-F02B; B14-G03; B14-H01; D05-H04



17/5/32 (Item 31 from file: 350)  
DIALOG(R) File 350:Derwent WPIX  
(c) 2006 The Thomson Corporation. All rts. reserv.

0013858580

WPI ACC NO: 2004-036945/200404

XRAM Acc No: C2004-014856

**Obtaining fractions of acid soluble proteins of micellar casein, useful in preventing or treating diabetes type I and/or II, obesity or intestinal disorders, comprises acidifying micellar casein or enzyme-treated casein to a pH below 6**

Patent Assignee: NESTEC SA (NEST)

Inventor: BOVETTO L; GREMLICH S; MACE C

Patent Family (4 patents, 99 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
EP 1367065	A1	20031203	EP 200277076	A	20020527	200404 B
WO 2005021589	A1	20050310	WO 2003EP9669	A	20030830	200520 NCE
AU 2003270130	A1	20050316	AU 2003270130	A	20030830	200534 NCE
			WO 2003EP9669	A	20030830	
BR 200318443	A	20060801	BR 200318443	A	20030830	200655 NCE
			WO 2003EP9669	A	20030830	

Priority Applications (no., kind, date): BR 200318443 A 20030830; AU 2003270130 A 20030830; WO 2003EP9669 A 20030830; EP 200277076 A 20020527

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
--------	------	-----	----	-----	--------------

EP 1367065	A1	EN	15	3	
------------	----	----	----	---	--

Regional Designated States,Original: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

WO 2005021589	A1	EN			
---------------	----	----	--	--	--

National Designated States,Original: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Regional Designated States,Original: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

AU 2003270130	A1	EN			
---------------	----	----	--	--	--

PCT Application WO 2003EP9669

Based on OPI patent WO 2005021589

BR 200318443	A	PT			
--------------	---	----	--	--	--

PCT Application WO 2003EP9669

Based on OPI patent WO 2005021589

#### Alerting Abstract EP A1

NOVELTY - Obtaining fractions of acid soluble proteins of micellar casein comprises acidifying micellar casein or enzyme-treated casein to a pH below 6.

DESCRIPTION - Obtaining fractions of acid soluble proteins of micellar casein comprises:

- 1.separating micellar or enzyme-treated casein and whey proteins;
- 2.acidifying micellar casein or enzyme-treated casein to a pH below 6;
- 3.separating acid soluble proteins from casein; and
- 4.separating different sub-fractions of cid soluble proteins.

INDEPENDENT CLAIMS are also included for the following:

- 1.a sub-fraction of acid soluble proteins from micellar casein obtainable by hydrophobic interaction chromatography and that the fraction is eluted from a hydrophobic stationary phase by a mobile phase comprising 26.4-36 or 43.2-46.4 vol.-% acetonitrile;
- 2.acid-soluble proteins from micellar casein for use as a medicament or preventive or therapeutic treatment of the human or animal body; and
- 3.a consumable product comprising any protein reaction or sub-fraction of (1) or (2).

ACTIVITY - Antidiabetic; Anorectic; Gastrointestinal-Gen.

No biological data given.

MECHANISM OF ACTION - None Given.

USE - The acid soluble proteins from the micellar casein is useful in preparing consumable products or medicaments for enhancing insulin secretion and/or proinsulin gene expression, increasing glucagon-like-peptide-1 (GLP-1) and/or GLP-2 secretion, regulating glucose concentration in **blood**, **decreasing gastric** emptying and acid secretion, regulating appetite, decreasing food intake, increasing satiety, increasing thickness and/or surface area of the intestinal mucosa, preventing or treating diabetes type I and/or II, obesity or intestinal disorders injury or dysfunctions (all claimed).

**Title Terms/Index Terms/Additional Words:** OBTAIN; FRACTION; ACID; SOLUBLE; PROTEIN; MICELLAR; CASEIN; USEFUL; PREVENT; TREAT; DIABETES; TYPE; OBESITY; INTESTINAL; DISORDER; COMPRISE; ACIDIC; ENZYME; PH; BELOW

**Class Codes**

International Classification (Main): C07K-014/47

(Additional/Secondary): A23J-003/32, A23J-003/34, A23L-001/305,

A61K-035/20, A61K-038/17, G01N-033/50

International Classification (+ Attributes)

IPC + Level Value Position Status Version

A23J-0001/20	A	I	R	20060101
A23L-0001/305	A	I	R	20060101
A61K-0038/00	A	N	R	20060101
C07K-0014/47	A	I	R	20060101
A23J-0001/00	C	I	R	20060101
A23L-0001/305	C	I	R	20060101
A61K-0038/00	C	N	R	20060101
C07K-0014/435	C	I	R	20060101

File Segment: CPI

DWPI Class: B04; D13

Manual Codes (CPI/A-M): B04-G01; B04-G21; B04-G22; B04-N02; B04-N04; B11-B; B14-E10; B14-E12; B14-S04; D03-H01T2

17/5/56 (Item 55 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0010671867 - Drawing available

WPI ACC NO: 2001-280602/

Related WPI Acc No: 1997-289068; 1997-415091; 1999-560002

XRAM Acc No: C2001-085069

XRPX Acc No: N2001-200023

**Treatment of bleeding site within gastrointestinal tract comprises**

**aspirating fluid from tract through elongated tube coupled to fluid recovery reservoir and treatment device**

Patent Assignee: ZIMMON SCI CORP (ZIMM-N)

Inventor: ZIMMON D S

**Patent Family** (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
US 6203520	B1	20010320	US 1995559564	A	19951116	200129 B
			US 1996597224	A	19960206	
			US 1997934248	A	19970919	
			US 1999359485	A	19990722	

Priority Applications (no., kind, date): US 1997934248 A 19970919; US 1996597224 A 19960206; US 1995559564 A 19951116; US 1999359485 A 19990722

**Patent Details**

Number	Kind	Lan	Pg	Dwg	Filing Notes
US 6203520	B1	EN	17	7	C-I-P of application US 1995559564 C-I-P of application US 1996597224 Division of application US 1997934248  C-I-P of patent US 5785684 Division of patent US 5947926

**Alerting Abstract US B1**

NOVELTY - A patient's gastrointestinal tract is treated by aspirating fluid from the tract through an elongated tube coupled to a treatment device slidable along the outer surface of tube placed into the tract and into a fluid recovery reservoir coupled to the tube; and advancing the treatment device along the tube toward a proximal portion adjacent the bleeding site.

DESCRIPTION - Treatment of a patient's gastrointestinal tract comprises:

1. placing an elongated tube (11) coupled to a fluid recovery reservoir and a treatment device slidable along the outer surface of the tube into the patient's gastrointestinal tract;
2. aspirating fluid from the patient's gastrointestinal tract through the elongated tube and into the fluid recovery reservoir; and
3. positioning the treatment device further by engaging the treatment device with a pusher (26) slidable on the tube and advancing the treatment device along the tube toward a proximal portion adjacent the bleeding site.

USE - For treating a bleeding site within a gastrointestinal tract.

ADVANTAGE - The invention controls gastrointestinal bleeding, i.e. esophagastric variceal bleeding, while permitting simultaneous and continuous irrigation and aspiration of the stomach. The method **inhibits** aspiration of **blood** and other **gastric** contents into the lungs and treats gastrointestinal bleeding without requiring advanced medical imaging and endoscopic equipment.

DESCRIPTION OF DRAWINGS - The figure shows a perspective view of a deflated esophagastric balloon tamponade device and irrigation tube of the invention.

- 11 Tube
- 20 Obturator
- 25 Balloon tamponade device
- 26 Pusher

**Title Terms/Index Terms/Additional Words:** TREAT; BLEED; SITE; GASTRO; TRACT  
; COMPRISE; ASPIRATE; FLUID; THROUGH; ELONGATE; TUBE; COUPLE; RECOVER;  
RESERVOIR; DEVICE

**Class Codes**

International Classification (Main): A61M-001/00  
US Classification, Issued: 604028000, 604500000

File Segment: CPI; EngPI

DWPI Class: B07; P34

Manual Codes (CPI/A-M): B04-B04D5; B11-B; B11-C04; B14-E04; B14-E10;  
B14-K01

**17/5/58 (Item 57 from file: 350)**

DIALOG(R) File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0010370691

WPI ACC NO: 2000-686816/200067

XRAM Acc No: C2000-208781

XRPX Acc No: N2000-507860

**Inhibiting endoleaks in a patient arising from endovascular repair of  
abdominal aortic aneurysms by embolizing blood vessels associated with the  
aneurysmal sac**

Patent Assignee: MICRO THERAPEUTICS INC (MICR-N)

Inventor: CRAGG A H; DOLMATCH B; GREFF R J; RICCI C

**Patent Family** (5 patents, 91 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
WO 2000056370	A1	20000928	WO 2000US7398	A	20000320	200067 B
AU 200039032	A	20001009	AU 200039032	A	20000320	200103 E
US 6303100	B1	20011016	US 1999273100	A	19990319	200164 E
EP 1163012	A1	20011219	EP 2000918170	A	20000320	200206 E
			WO 2000US7398	A	20000320	
JP 2002539853	W	20021126	JP 2000606274	A	20000320	200307 E
			WO 2000US7398	A	20000320	

Priority Applications (no., kind, date): US 1999273100 A 19990319

**Patent Details**

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 2000056370	A1	EN	37	0	

National Designated States, Original: AE AG AL AM AT AU AZ BA BB BG BR BY  
CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS  
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT  
RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Regional Designated States, Original: AT BE CH CY DE DK EA ES FI FR GB GH  
GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW

AU 200039032 A EN Based on OPI patent WO 2000056370

EP 1163012 A1 EN PCT Application WO 2000US7398

Based on OPI patent WO 2000056370

Regional Designated States, Original: AL AT BE CH CY DE DK ES FI FR GB GR  
IE IT LI LT LU LV MC MK NL PT RO SE SI

JP 2002539853 W JA 33 PCT Application WO 2000US7398

Based on OPI patent WO 2000056370

**Alerting Abstract WO A1**

NOVELTY - Inhibiting endoleaks in a patient arising from endovascular  
repair of abdominal aortic aneurysms comprising embolizing blood vessels

associated with the aneurysmal sac including delivering through a microcatheter a biocompatible fluid composition to the vessels under solidifying conditions, is new.

DESCRIPTION - Inhibiting endoleaks in a patient arising from endovascular repair of abdominal aortic aneurysms comprising embolizing blood vessels associated with the aneurysmal sac including delivering through a microcatheter a biocompatible fluid composition to the vessels under solidifying conditions, is new. The aneurysm is repaired by catheter delivery of an endovascular prosthesis to the site of the aneurysm, thus inhibiting blood flow into the aneurysm.

An INDEPENDENT CLAIM is also included for sealing endoleaks formed after placement of an endovascular prosthesis in a mammal, comprising:

1. identifying an abdominal aortic aneurysm in a patient;
2. endovascularly repairing the aneurysm by catheter delivery of an endovascular prosthesis to the aneurysm site;
3. identifying endoleaks after placement of the prosthesis; and
4. delivering through a microcatheter to the sites of endoleaks a fluid composition under conditions where it forms a coherent adhesive mass

~in situ ~, sealing the endoleaks.

USE - For inhibiting endoleaks in a patient arising from endovascular repair of abdominal aortic aneurysms.

ADVANTAGE - The invention provides a reliable endovascular method to inhibit endoleaks with endovascular graft repair of abdominal aortic aneurysms.

**Title Terms/Index Terms/Additional Words:** INHIBIT; PATIENT; ARISE; REPAIR; ABDOMEN; AORTA; ANEURYSM; BLOOD; VESSEL; ASSOCIATE; SAC

#### **Class Codes**

International Classification (Main): A61K-051/00, A61L-031/00

(Additional/Secondary): A61B-017/00, A61K-047/08, A61K-047/10, A61K-047/20, A61K-047/32, A61K-047/38, A61K-049/04, A61M-025/00, A61M-036/14

US Classification, Issued: 424001290, 424001730, 424001650, 424009100

File Segment: CPI; EngPI

DWPI Class: A96; B05; B07; D22; P31; P34

Manual Codes (CPI/A-M): A08-S02; A12-V; B04-C02A3; B04-C03B; B05-A01B; B05-A03B; B10-A07; B10-D03; B11-C04B; B14-F02; D09-C01

**17/5/59 (Item 58 from file: 350)**

DIALOG(R) File 350: Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0010034048 - Drawing available

WPI ACC NO: 2000-338844/200029

XRPX Acc No: N2000-254376

**Intraluminal device for treatment of aneurysms and stenotic lesions has an expandable tubular body incorporating tabs that initially lie flat on the body or project inwards from it but which project outwards when the body is expanded**

Patent Assignee: DEHDASHTIAN M (DEHD-I); EDWARDS LIFESCIENCES CORP (EDWA-N); WHITE G (WHIT-I); WHITE G H (WHIT-I)

Inventor: DEHDASHTIAN M; WHITE G H

Patent Family (7 patents, 88 countries)

Patent Application

Number	Kind	Date	Number	Kind	Date	Update
WO 2000018322	A1	20000406	WO 1999AU832	A	19990929	200029 B
AU 199963207	A	20000417	AU 199963207	A	19990929	200035 E
EP 1123063	A1	20010816	EP 1999950401	A	19990929	200147 E
			WO 1999AU832	A	19990929	
US 20020123790	A1	20020905	US 2001966567	A	20010927	200260 NCE
JP 2002525162	W	20020813	WO 1999AU832	A	19990929	200267 E
			JP 2000571845	A	19990929	
AU 767566	B	20031113	AU 199963207	A	19990929	200381 E
AU 2004200295	A1	20040219	AU 2004200295	A	20040128	200445 E

Priority Applications (no., kind, date): AU 2004200295 A 20040128; US 2001966567 A 20010927; AU 19986243 A 19980929

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 2000018322	A1	EN	33	7	
National Designated States, Original: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
Regional Designated States, Original: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW					
AU 199963207	A	EN			Based on OPI patent WO 2000018322
EP 1123063	A1	EN			PCT Application WO 1999AU832
					Based on OPI patent WO 2000018322
Regional Designated States, Original: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
JP 2002525162	W	JA	37		PCT Application WO 1999AU832
					Based on OPI patent WO 2000018322
AU 767566	B	EN			Previously issued patent AU 9963207
					Based on OPI patent WO 2000018322
AU 2004200295	A1	EN			Division of patent AU 767566

#### Alerting Abstract WO A1

NOVELTY - The intraluminal device (10) comprises an expandable tubular body, capable of bridging an aneurysm or of stenting a stenotic vessel, with a number of moveable tabs attached to or integral with its surface. The aorta (11) is connected to the left and right femoral arteries (14,15), with the aortic aneurysms located between the renal arteries (16,17) and bifurcation of the aorta (18).

DESCRIPTION - When the device body is radially compressed prior to insertion, the tabs either lie flat on the body surface or project inwards from it but when the body is expanded within the target vessel, they project outwards to engage the vessel walls.

USE - As an intraluminal device for the treatment of aneurysms and stenotic lesions.

ADVANTAGE - The tabs enable the device to anchor itself within the walls of the lumen in which it is installed. Some tabs may be allowed to remain projecting inwards to provide a means for future engagement of instruments or other devices.

DESCRIPTION OF DRAWINGS - The drawings show diagrammatic longitudinal views of the device in its radially compressed and expanded states.

- 10 Intraluminal device
- 11 Aorta
- 14,15 Left and right femoral arteries
- 16,17 Renal arteries
- 18 Bifurcation of the aorta

Title Terms/Index Terms/Additional Words: DEVICE; TREAT; ANEURYSM; LESION;

EXPAND; TUBE; BODY; INCORPORATE; TAB; INITIAL; LIE; FLAT; PROJECT; INWARD  
; OUTWARD

#### Class Codes

International Classification (Main): A61F-002/06, A61M-029/02

(Additional/Secondary): A61M-029/00

US Classification, Issued: 623001140, 623001360, 623001350, 623001310

File Segment: EngPI; ;

DWPI Class: P32; P34

17/5/63 (Item 62 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0009681055

WPI ACC NO: 1999-024164/199902

XRAM Acc No: C1999-007422

**Use of tissue factor - to influence formation of blood vessels, e.g., in treatment of wounds**

Patent Assignee: MERCKLE GMBH (MERC); MERCKLE GMBH CHEM PHARM FAB (MERC)

Inventor: NAKAGAWA K; NAWROTH P; ZHANG Y

**Patent Family** (15 patents, 80 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
WO 1998051321	A1	19981119	WO 1998DE1306	A	19980508	199902 B
DE 19719652	A1	19981203	DE 19719652	A	19970509	199903 E
AU 199883315	A	19981208	AU 199883315	A	19980508	199916 E
NO 199905459	A	19991108	WO 1998DE1306	A	19980508	200008 E
			NO 19995459	A	19991108	
EP 980251	A1	20000223	EP 1998933500	A	19980508	200015 E
			WO 1998DE1306	A	19980508	
CZ 199903912	A3	20000412	WO 1998DE1306	A	19980508	200026 E
			CZ 19993912	A	19980508	
HU 200003831	A2	20010228	WO 1998DE1306	A	19980508	200121 E
			HU 20003831	A	19980508	
MX 199910214	A1	20000701	MX 199910214	A	19991108	200134 E
JP 2001527555	W	20011225	JP 1998548691	A	19980508	200204 E
			WO 1998DE1306	A	19980508	
AU 746782	B	20020502	AU 199883315	A	19980508	200238 E
EP 980251	B1	20020821	EP 1998933500	A	19980508	200262 E
			WO 1998DE1306	A	19980508	
DE 59805246	G	20020926	DE 59805246	A	19980508	200271 E
			EP 1998933500	A	19980508	
			WO 1998DE1306	A	19980508	
ES 2184299	T3	20030401	EP 1998933500	A	19980508	200328 E
CZ 293005	B6	20040114	WO 1998DE1306	A	19980508	200429 E
			CZ 19993912	A	19980508	
US 6930094	B1	20050816	WO 1998DE1278	A	19980507	200554 E
			WO 1998DE1306	A	19980508	
			US 2000423712	A	20000825	

Priority Applications (no., kind, date): WO 1998DE1306 A 19980508; DE 19719652 A 19970509; WO 1998DE1278 A 19980507

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 1998051321	A1	DE	28	3	

National Designated States, Original: AL AM AT AU AZ BA BB BG BR BY CA CH  
CN CU CZ DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK

LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ  
 TM TR TT UA UG US UZ VN YU ZW

Regional Designated States, Original: AT BE CH CY DE DK EA ES FI FR GB GH  
 GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

AU 199883315 A EN Based on OPI patent WO 1998051321  
 NO 199905459 A NO PCT Application WO 1998DE1306  
 EP 980251 A1 DE PCT Application WO 1998DE1306  
 Based on OPI patent WO 1998051321

Regional Designated States, Original: AT BE CH DE DK ES FI FR GB GR IE IT  
 LI LU MC NL PT SE SI

CZ 199903912 A3 CS PCT Application WO 1998DE1306  
 Based on OPI patent WO 1998051321

HU 200003831 A2 HU PCT Application WO 1998DE1306  
 Based on OPI patent WO 1998051321

JP 2001527555 W JA 22 PCT Application WO 1998DE1306  
 Based on OPI patent WO 1998051321

AU 746782 B EN Previously issued patent AU 9883315

EP 980251 B1 DE Based on OPI patent WO 1998051321  
 PCT Application WO 1998DE1306  
 Based on OPI patent WO 1998051321

Regional Designated States, Original: AT BE CH DE DK ES FI FR GB GR IE IT  
 LI LU MC NL PT SE SI

DE 59805246 G DE Application EP 1998933500  
 PCT Application WO 1998DE1306  
 Based on OPI patent EP 980251  
 Based on OPI patent WO 1998051321

ES 2184299 T3 ES Application EP 1998933500  
 Based on OPI patent EP 980251

CZ 293005 B6 CS PCT Application WO 1998DE1306  
 Previously issued patent CZ 9903912

US 6930094 B1 EN Based on OPI patent WO 1998051321  
 1998DE1278 Continuation of application WO  
 PCT Application WO 1998DE1306  
 Based on OPI patent WO 1998051321

#### Alerting Abstract WO A1

Use of tissue factor (I) or its fragment, to influence formation of blood vessels.

USE - (I) is a transmembrane glycoprotein which can bind the blood clotting factors VII or VIIa for activation of blood vessel formation, e.g., for replacing aged blood vessels. (I) may thus be used in wound healing to treat paraplegia, leprosy or neuropathies; in the treatment or prevention of stroke or infarct, senile dementia, arteriosclerosis, Crohn's disease or diabetic retinopathy, diabetes mellitus, vasculitis, arterial occlusions or gastric ulcers. Antibodies to (I), or a nucleic acid which has an antisense effect on the expression of (I), may be used to **inhibit** formation of **blood** vessels, especially in treatment of tumours.

**Title Terms/Index Terms/Additional Words:** TISSUE; FACTOR; INFLUENCE; FORMATION; BLOOD; VESSEL; TREAT; WOUND

#### Class Codes

International Classification (Main): A61K, A61K-038/00, A61K-038/14, A61K-038/36, A61K-045/00, A61K-048/00  
 (Additional/Secondary): A61K-031/70, A61K-031/711, A61K-038/19, A61K-039/395, A61P-017/02, A61P-035/00, A61P-043/00, A61P-009/00, A61P-009/14, C07K-014/745, C12N-015/09, C12N-015/12, C12N-015/74, C12N-005/02



US Classification, Issued: 514044000, 424093210, 435320100, 435325000,  
435455000

File Segment: CPI

DWPI Class: B04

Manual Codes (CPI/A-M): B04-E06; B04-G02; B04-H19; B14-E08; B14-H01;  
B14-J01A4; B14-N16; B14-N17B; B14-S04

**17/5/65 (Item 64 from file: 350)**

DIALOG(R)File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0009284959 - Drawing available

WPI ACC NO: 1999-214593/

Related WPI Acc No: 1998-437102

XRPX Acc No: N1999-157943

**Surgical clamp for temporarily compressing body conduit, featuring rigid base and resilient pad on clamp jaws**

Patent Assignee: APPLIED MEDICAL RESOURCES CORP (MEDI-N)

Inventor: CHI-SING E; FISHBURN R; GADBERRY D L; HART C C; YAWATA H

**Patent Family** (3 patents, 21 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
WO 1999011179	A1	19990311	WO 1998US18296	A	19980903	199918 B
EP 1009292	A1	20000621	EP 1998945856	A	19980903	200033 E
			WO 1998US18296	A	19980903	
JP 2001514036	W	20010911	WO 1998US18296	A	19980903	200167 E
			JP 2000508291	A	19980903	

Priority Applications (no., kind, date): US 1997923211 A 19970904

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 1999011179	A1	EN	30	26	
National Designated States,Original: CA JP US					
Regional Designated States,Original: AT BE CH CY DE DK ES FI FR GB GR IE					
IT LU MC NL PT SE					
EP 1009292	A1	EN			PCT Application WO 1998US18296 Based on OPI patent WO 1999011179
Regional Designated States,Original: DE FR GB					
JP 2001514036	W	JA	40		PCT Application WO 1998US18296 Based on OPI patent WO 1999011179

#### Alerting Abstract WO A1

NOVELTY - The opposing faces of the clamp's jaws (14, 16) each carry a removable insert (43) on whose rigid base (45) is mounted a resilient pad (47). A cover (50), made of a material designed to provide good frictional contact with a body conduit, surrounds each pad's exposed face (90) and sides (92, 94). The cover may be a tight or loose fit over the pad.

USE - For temporarily compressing a body conduit, e.g. **intestine** or **blood** vessel, in order to **reduce** or occlude **flow** within it.

ADVANTAGE - As the clamp is tightened, the resilient pads deform to bring progressively more of the friction material on the inserts' sides into contact with the conduit, increasing the resistance to movement of the clamp relative to the conduit.

DESCRIPTION OF DRAWINGS - The drawing is a partial transverse cross-section through the clamp's jaws showing the deformed inserts gripping a body conduit.

14, 16 Jaws

43 Insert

45 Rigid base of insert

47 Resilient pad  
50 Cover  
90 Central section of cover  
92, 94 Sides of cover.

**Title Terms/Index Terms/Additional Words:** SURGICAL; CLAMP; TEMPORARY;  
COMPRESS; BODY; CONDUIT; FEATURE; RIGID; BASE; RESILIENT; PAD; JAW

**Class Codes**

International Classification (Main): A61B-017/08, A61B-017/12

File Segment: EngPI; ;  
DWPI Class: P31

17/5/69 (Item 68 from file: 350)  
DIALOG(R)File 350:Derwent WPIX  
(c) 2006 The Thomson Corporation. All rts. reserv.

0008520284  
WPI ACC NO: 1998-051861/  
XRAM Acc No: C1998-017694

**Identifying compounds useful as hypotensive or hypertensive agents - by determining their ability to relax or stimulate tension in mesenteric resistance arteries**

Patent Assignee: UNIV TEXAS SYSTEM (TEXA)  
Inventor: BIAN K; BUKOSKI R D

**Patent Family** (3 patents, 74 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
WO 1997042951	A1	19971120	WO 1997US9097	A	19970516	199805 B
AU 199731467	A	19971205	AU 199731467	A	19970516	199814 E
US 6184254	B1	20010206	US 199618367	P	19960516	200109 E
			WO 1997US9097	A	19970516	
			US 1998180730	A	19981113	

Priority Applications (no., kind, date): US 1998180730 A 19981113; US 199618367 P 19960516

**Patent Details**

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 1997042951	A1	EN	65	18	
National Designated States,Original: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU					
Regional Designated States,Original: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG					
AU 199731467	A	EN			Based on OPI patent WO 1997042951
US 6184254	B1	EN			Related to Provisional US 199618367 PCT Application WO 1997US9097 Based on OPI patent WO 1997042951

**Alerting Abstract WO A1**

Identifying a compound which modulates vascular tone via Ca<sup>2+</sup> receptors of perivascular sensory nerves comprises: (a) contacting a mesenteric resistance artery (freed of endothelial tissue) with a compound and measuring arterial tension changes induced by the compound; (b) when tension is relieved by the compound, assuring intactness of perivascular sensory nerve Ca<sup>2+</sup> receptor by measuring tension release of the artery by

contact with extracellular  $\text{Ca}^{2+}$ ; (c) repeating the tension assay with the compound, but after pretreatment of the mesenteric resistance artery with a  $\text{Ca}^{2+}$  receptor blocker, where the blocker obviates the decrease in tension caused by the compound (when it has vasodilatory activity); and (d) measuring effects of compounds (which yield positive results in steps (a) and (c)) on mesenteric resistance arteries from animals subject to chronic sensory denervation by neonatal treatment, a lack of vasorelaxation being a further positive result. Compounds which have vasomodulating activity (by stimulation or inhibition of perivascular sensory nerve  $\text{Ca}^{2+}$  receptors) modulate tension in the arteries of step (a), but not in those of steps (c) or (d).

USE - The process is useful for identifying compounds useful in treatment of e.g. hypertension or hypotension, angina, stroke, vasospasm, traumatic brain injury, spastic colon, intestinal cramping associated with inflammatory bowel disease, impotence, diabetic vascular injury associated with degenerative perivascular nerve function, preeclampsia and bronchospasm.

**Title Terms/Index Terms/Additional Words:** IDENTIFY; COMPOUND; USEFUL; HYPOTENSIVE; HYPERTENSIVE; AGENT; DETERMINE; ABILITY; RELAX; STIMULATING; TENSION; MESENTERY; RESISTANCE; ARTERY

**Class Codes**

International Classification (Main): A01N-033/02, A61K-031/44

(Additional/Secondary): A61K-031/135, A61K-049/00, G01N-033/53

US Classification, Issued: 514653000, 514673000, 514674000, 514920000, 514930000, 514290000, 424009200, 435003000, 435007100

File Segment: CPI

DWPI Class: B04

Manual Codes (CPI/A-M): B11-C08E1; B12-K04A

17/5/73 (Item 72 from file: 350)  
DIALOG(R)File 350:Derwent WPIX  
(c) 2006 The Thomson Corporation. All rts. reserv.

0008023840

WPI ACC NO: 1997-117184/

XRPX Acc No: N1997-096616

**Surgical treatment procedure for duodenal ulcers - reducing blood flow to stomach through left gastric artery and right gastro-omental artery.**

Patent Assignee: KOZLOV V A (KOZL-I)

Inventor: IVANOV V V; KOZLOV V A; STOLIN A V

**Patent Family** (1 patents, 1 countries)

Patent		Application				Update	
Number	Kind	Date	Number	Kind	Date		
RU 2063174	C1	19960710	RU 199313385	A	19930315	199711	B

Priority Applications (no., kind, date): RU 199313385 A 19930315

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
RU 2063174	C1	RU	5	0	

#### Alerting Abstract RU C1

The procedure consists of surgical intervention aimed at reducing the production of acid in the stomach and correcting the intragastric blood flow. This is achieved by isolating the left gastric artery by ligation on the proximal side of its descending branch, and the gastro-omental artery on a level with the intermediate sulcus of the stomach.

The operation is performed using an upper central laparotomy, is quickly performed, and avoids cutting into the stomach wall.

ADVANTAGE - Reduced trauma and post-operative complications, retaining stomach's innervation.

**Title Terms/Index Terms/Additional Words:** SURGICAL; TREAT; PROCEDURE; DUODENAL; ULCER; REDUCE; BLOOD; FLOW; STOMACH; THROUGH; LEFT; GASTRIC; ARTERY; RIGHT; GASTRO; OMENTAL

#### Class Codes

International Classification (Main): A61B-017/00

File Segment: EngPI; ;

DWPI Class: P31

17/5/79 (Item 78 from file: 350)  
DIALOG(R)File 350:Derwent WPIX  
(c) 2006 The Thomson Corporation. All rts. reserv.

0007338650

WPI ACC NO: 1995-402561/

XRPX Acc No: N1995-291379

**Modelling of correction of portal hypertension in animals - includes correction of portal blood flow by constriction of opening of celiac tube and cranial and caudal mesenteric arteries by 1/3 dia.**

Patent Assignee: TERN MED INST (TEME-R)

Inventor: GERASIMYUK I E; VAIDA A R; VAIDA R I

**Patent Family** (1 patents, 1 countries)

Patent		Application				Update	
Number	Kind	Date	Number	Kind	Date		
RU 2033642	C1	19950420	SU 4924876	A	19910403	199551	B

Priority Applications (no., kind, date): SU 4924876 A 19910403

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
RU 2033642	C1	RU	3	0	

#### Alerting Abstract RU C1

Simultaneous restriction is carried out of the openings of the arterial celiac tube and of the caudal mesenteric artery to 1/3 dia., redg. the **blood flow** through the **constricted** vessels and organs of the peritoneal cavity.

This eliminates the possibility of forming of a collateral blood flow between the system of the celiac tube and the cranial **mesenteric artery** and between the cranial and caudal **mesenteric arteries**.

USE/ADVANTAGE - Correction of portal hypertension. Reduced traumatisation of operation. Bul.11/20.4.95

**Title Terms/Index Terms/Additional Words:** MODEL; CORRECT; PORTAL; HYPERTENSIVE; ANIMAL; BLOOD; FLOW; CONSTRICT; OPEN; TUBE; CRANIUM; CAUDAL; MESENTERY; ARTERY; DIAMETER

#### Class Codes

International Classification (Main): G09B-023/28

File Segment: EngPI; ;

DWPI Class: P85

17/5/80 (Item 79 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0007164829 - Drawing available

WPI ACC NO: 1995-203831/

XRAM Acc No: C1995-094396

**New peptide(s) corresp. to albumin partial sequences - used as hypotensives, antagonising prostaglandin-F2alpha-induced mesenteric artery constriction**

Patent Assignee: ITO HAM KK (ITOH-N)

Inventor: KASHIMOTO K; YOSHIKAWA M

**Patent Family** (1 patents, 1 countries)

Patent		Application				
Number	Kind	Date	Number	Kind	Date	Update
JP 7118292	A	19950509	JP 1993289888	A	19931026	199527 B

Priority Applications (no., kind, date): JP 1993289888 A 19931026

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
JP 7118292	A	JA	8	0	

#### Alerting Abstract JP A

Physiologically active peptides of formula (I) and their salts are new. H-(A)-(B)-(C)-(D)-(E)-(F)-Leu-(G)-(H)-OH (I). (A) = Arg-His-Pro-Asp, His-Pro-Asp or direct bond; (B) = Tyr or Val; (C) = Ala or Ser; (D) = Val or Ile; (E) = Val, Ser or Thr; (F) = Leu or Val; (G) = Leu or Val; (H) = Arg or Lys. Pref. (I) corresponds to 337-348, 338-348 and 341-348 peptides of human serum albumin or 337-348, 338-348 and 341-348 peptides of porcine and rat serum albumin.

USE - (I) are hypotensives which cause dilation of ilium and **mesenteric artery constricted** by PGF2alpha.

**Title Terms/Index Terms/Additional Words:** NEW; PEPTIDE; CORRESPOND; ALBUMIN ; SEQUENCE; HYPOTENSIVE; ANTAGONIST; INDUCE; MESENTERY; ARTERY; CONSTRICT

**Class Codes**

International Classification (Main): C07K-007/06  
(Additional/Secondary): A61K-038/00, A61K-038/55, C07K-007/08

File Segment: CPI

DWPI Class: B04

Manual Codes (CPI/A-M): B04-C01B; B04-N02B; B14-F02B

**17/5/81 (Item 80 from file: 350)**

DIALOG(R) File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0006474011

WPI ACC NO: 1993-279373/

XRPX Acc No: N1993-214601

**Large intestine lavage probe - Tubes have closed ends and outer tube bears electric heating plate with conductor for connection to electricity supply source**

Patent Assignee: SENYUTOVICH R V (SENY-I)

Inventor: SENYUTOVICH R V; TSYMBALYUK V P

**Patent Family** (1 patents, 1 countries)

Patent			Application			Update	
Number	Kind	Date	Number	Kind	Date		
SU 1755805	A1	19920823	SU 4626494	A	19881121	199335	B

Priority Applications (no., kind, date): SU 4626494 A 19881121

**Patent Details**

Number	Kind	Lan	Pg	Dwg	Filing Notes
SU 1755805	A1	RU	2	1	

**Alerting Abstract SU A1**

The probe has outer (2) and inner (1) tubes with apertures in their working ends. The tubes (1,2) are made with closed ends. On the outer tube (2) there is an electric heating plate (4) equipped with a conductor for electrical connection (5) to a source of electricity supply.

USE/ADVANTAGE - As a probe for lavage of the large **intestine** , **reducing blood** loss in perforation of the wall of the intestine. Bul. 31/23.8.92

**Title Terms/Index Terms/Additional Words:** INTESTINAL; LAVAGE; PROBE; TUBE; CLOSE; END; OUTER; BEAR; ELECTRIC; HEAT; PLATE; CONDUCTOR; CONNECT; SUPPLY; SOURCE

**Class Codes**

International Classification (Main): A61M-009/00

File Segment: EngPI; ;

DWPI Class: P34

**17/5/88 (Item 87 from file: 350)**

DIALOG(R) File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0004325647 - Drawing available

WPI ACC NO: 1988-055586/

XRPX Acc No: N1988-042018

**Oesophagoplasty left half large intestine graft vascularisation - by making auxiliary vascular arch from inferior mesenteric artery segment**

Patent Assignee: A MED SURGERY RES (AMSU-R)

Inventor: ANDRIANOV V A; CHERNOUSOV A F; KORCHAK A M

**Patent Family** (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
SU 1324651	A	19870723	SU 4033084	A	19860304	198808 B

Priority Applications (no., kind, date): SU 4033084 A 19860304

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
SU 1324651	A	RU	4	1	

#### Alerting Abstract SU A

According to the proposed method, an auxiliary vascular arch is made from a segment of the inferior mesenteric artery. This is done by ligating the artery at the points above divergence (5) of the left colic artery (2) and below the divergence of the right sigmoid artery (3). The large intestine is mobilised and its vascular system is examined. If with good Riolan's arch (1) loose vascular branching is found, the main trunk of the **mesenteric artery** is prepd. A test **constriction** of the **artery** is made above divergence point (5) of the left colic artery, and below the divergence of the sigmoid **artery**. The inferior **mesenteric artery** is ligated and cut at the above level.

**ADVANTAGE** - **Reduces** adequate **blood** circulation when isolating a graft from the left half of the large intestine with loose branching of the vessels. Bul. 27/23.7.87

**Title Terms/Index Terms/Additional Words:** LEFT; HALF; INTESTINAL; GRAFT; AUXILIARY; VASCULAR; ARCH; INFERIOR; SEGMENT

#### Class Codes

(Additional/Secondary): A61B-017/00

File Segment: EngPI; ;

DWPI Class: P31

17/5/89 (Item 88 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0003413937

WPI ACC NO: 1985-183485/

XRAM Acc No: C1985-080221

**New synthetic urotensin peptide and analogues - useful for lowering blood pressure, changing regional blood distribution, increasing e.g. ACTH secretion etc.**

Patent Assignee: SALK INST BIOLOGICAL STUDIES (SALK)

Inventor: LEDERIS K P; MACCANNELL K L; RIVIER J E F

**Patent Family** (2 patents, 2 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
US 4528189	A	19850709	US 1983463397	A	19830203	198530 B

CA 1247600

A 19881228

198905 E

Priority Applications (no., kind, date): US 1983463397 A 19830203

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
US 4528189	A	EN	7	0	
CA 1247600	A	EN			

#### Alerting Abstract US A

Synthetic polypeptides of formula (I) and their nontoxic addn. salts are new:

Y-R1-Pro-Pro-Ile-Ser-Ile-Asp-Leu -Thr-Phe-His-Leu-Leu-Arg-Asn-Met-Ile  
-Gln-Met-Ala-Arg-Ile-Glu-Asn-Glu-Arg -Glu-Gln-Ala-Gly-Leu-Asn-Arg-Lip-Tyr  
-Leu-Asp-Glu-Val-NH2 (I)

(where Y = H or acyl of up to 7C; and R1 = Asn-Asp-Asp, Asp-Asp, Asp, Ala or des-R1).

Also claimed are (i) compsns. for lowering blood pressure or for changing regional blood distribution comprising (I) as active agent, pref. for increasing intestinal blood flow and/or lowering blood pressure; and (ii) a method of elevating the secretion of ACTH and corticosteroids or beta-endorphin-like secretions employing (I).

USE - (I) are synthetic Urotensin I and fragments. (I) are useful for regulating beta-lipotropin secretion and/or for affecting mood, behavioural and gastrointestinal functions, in mesenteric ischemia (ischemic bowel syndrome, -intestinal ulceration, -colitis, -proctitis, etc), in anastomotic gut surgery (to increase blood supply to the wound and promote healing), in shock and hypertension where **decreased intestinal blood flow** is involved, and heart failure or other cardiac conditions where 'afterload' reduction is desirable, in inflammatory bowel disease etc. Doses are e.g. 0.01-200 micro g/kg.

**Title Terms/Index Terms/Additional Words:** NEW; SYNTHETIC; PEPTIDE; ANALOGUE ; USEFUL; LOWER; BLOOD; PRESSURE; CHANGE; REGION; DISTRIBUTE; INCREASE; ACTH; SECRETION; ADRENOCORTICAL; HORMONE; CORTICOTROPHIN

#### Class Codes

(Additional/Secondary): A61K-037/02, C07C-103/52, C07K-007/10  
US Classification, Issued: 514012000, 530324000, 930DIG, 930010000, 930020000

File Segment: CPI

DWPI Class: B04

Manual Codes (CPI/A-M): B04-C01; B12-A07; B12-D07; B12-D10; B12-E08; B12-F01; B12-F05; B12-G01; B12-G04; B12-J01

17/5/90 (Item 89 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0003167337

WPI ACC NO: 1984-265207/

XRAM Acc No: C1984-112174

**Corticotropin releasing factor polypeptide(s) and analogues - useful for regulation of secretion of ACTH, lowering blood pressure, etc.**

Patent Assignee: SALK INST BIOLOGICAL STUDIES (SALK); SALK INST FOR BIOLOGY (SALK)

Inventor: RIVIER J E F; SPIESS J; VALE W W

**Patent Family** (14 patents, 20 countries)

Patent Application



Number	Kind	Date	Number	Kind	Date	Update
EP 122798	A	19841024	EP 1984302558	A	19840413	198443 B
AU 198426777	A	19841018				198449 E
JP 59199662	A	19841112	JP 198472606	A	19840411	198451 E
DK 198401697	A	19841015				198503 E
US 4489163	A	19841218	US 1983484931	A	19830414	198505 E
ZA 198402460	A	19840926	ZA 19842460	A	19840402	198508 E
ES 198606406	A	19861001	ES 1984531585	A	19840413	198649 E
IL 71326	A	19871130				198803 E
CA 1247602	A	19881228				198905 E
KR 199006559	B	19900913				199139 E
EP 122798	B1	19931103	EP 1984302558	A	19840413	199344 E
DE 3486238	G	19931209	DE 3486238	A	19840413	199350 E
			EP 1984302558	A	19840413	
JP 1994089034	B2	19941109	JP 198472606	A	19840411	199443 E
DK 172682	B	19990525	DK 19841697	A	19840327	199927 E

Priority Applications (no., kind, date): US 1983484931 A 19830414

#### Patent Details

Number	Kind	Lan	Pg	Dwg	Filing	Notes
EP 122798	A	EN	31	0		
Regional Designated States, Original: AT BE CH DE FR GB IT LI LU NL SE						
US 4489163	A	EN		0		
ZA 198402460	A	EN				
IL 71326	A	EN				
CA 1247602	A	EN				
EP 122798	B1	EN	30	0		
Regional Designated States, Original: AT BE CH DE FR GB IT LI LU NL SE						
DE 3486238	G	DE			Application	EP 1984302558
					Based on OPI patent	EP 122798
JP 1994089034	B2	JA	10		Based on OPI patent	JP 59199662
DK 172682	B	DA			Previously issued patent	DK 8401697

#### Alerting Abstract EP A

Peptides of formula (I) and their nontoxic addn. salts are new  
R1-Pro-Pro-Ile-Ser-R8-R9 -Leu-R11-R12-R13-Leu-Leu  
Arg-R17-R18-R19-Glu-R21-R22 -R23-R24-R25-R26-R27-R28  
R29-Gln-Ala-R32-R33-Asn -Arg-R36-R37-R38 -R39-R40-R41 (I) (where R1 = Glu, Gln-Glu, pGlu-Gly, Ser-Gln-Glu, D-Ser-Gln-Glu, Ser-Glu-Glu, D-Ser-Glu-Glu, Glu-Glu, D-pGlu-Gly or desR1; R8, R12, R19 and R29 each = Leu, Ile, Ala, Gly, Val, Nle, Phe, or Gln; R9 = Asp or Glu; R11 = Thr or Ser; R13 = His, Tyr or Glu; R17 = Glu or Lys; R18 = Val, Nle or Met; R21 = Met, Nva, Ile, Ala, Leu, Nle, Val, Phe or Gln; R22 = Ala, Thr, Asp or Glu; R23 = Arg, Orn, Har or Lys; R25 = Asp or Glu; R26 = Gln, Asn, or Lys; R27 = Leu, Ile, Ala, Val, Nva, Met, Nle, Phe, Asp, Asn, Gln or Glu; R28 = Ala, Arg or Lys; R29 = Gln or Glu; R32 = His, Gly, Tyr or Ala; R33 = Ser, Asn, Leu, Thr or Ala; R36 = Lys, Orn, Arg, Har or Leu; R37 = Leu or Tyr; R39 = Met or Leu; R39 = Glu or Asp; R40 = Ile, Thr, Glu, Ala, Val, Leu, Nle, Phe, Nva, Gly or Gln; R41 = Ala, Ile, Gly, Val, Leu, Nle, Phe, Gln or des R41; provided that when R38 = Leu, then R22 is Ala and/or R33 is Leu.

USES/ADVANTAGES - (I) are human or rat corticotropin releasing factor (CRF) or analogues (I) may be admin. to humans or animals for regulation or secretion of ACTH, beta-endorphin, beta-lipotropin, other prods. of the pro-opiomelanocortin gene and corticosterone and/or for lowering blood pressure and/or for affecting mood, behavioural and gastrointestinal functions and autonomic nervous system activities.

#### Equivalent Alerting Abstract US A

Peptide derivs. of sauvagine being corheotropin releasing factors CRF of

the formula (I) and their non-toxic salts are new.

Y-R1-Pro-Pro-Ile-Ser-R8-Asp-Leu-R11- R12-R13-Leu-Leu-Arg-  
R17-R18-R19-Glu-R21-R22-R23-R24-R25 R26-R27-R28-Glu-Gln-  
Ala-R32-R33-Asn-Arg-R36-Leu-R38-R39- R40-R41-NH2

(Y = 11 or 1-7C acyl; R1 = Ser-Gln-Glu, pGlu-Gly, Glu, D-Ser-Gln-Glu, Ser-Glu-Glu, D-Ser-Glu-Glu, Glu-Glu, D-pGlu-Gly or des R1, R8. R12, R19, R24 and R40 = Leu, Ile, Ala, Gly, Val, Nle, Rhe or Gln; R4 = Thr or Ser; R13 = His, Tyr or Glu; R17 = Glu or Lys; R18 = Val or Met; R21 = Met, niet(O), Ile, Ala, Leu, Gly, Nle, Val, Phe or Gln; R22 = Ala or Thr or Glu; R23 = Arg or Lys; R25 = Asp or Glu; R26 = Gln or Lys; R27 = Leu, Ile, Ala, Gly, Val, Nle, Phe, Asp, Asn, Gln, or Glu; R28 = Ala or Lys; R32 = His, Tyr or Ala; R33 = Ser, Asn, Leu, Thr or Ala; R36 = Lys or Leu, R38 = Met or Leu, R39 = Glu or Asp, R41 = Ala, Ileu; Gly, Val, Leu, Nle, Phe, Gln or des R41, provided that when R38 = Leu then R22 is Ala or non-toxic addition salt.)

USE - (I) lowers mammalian **blood** pressure, **reduces** **gastric** acid production, ACTH secretion modulator, beta-END-LI secretion inhibitor, corticosteroid modulus and is an agent for evaluating hypothalamic pituitary adrenal function.

**Title Terms/Index Terms/Additional Words:** CORTICOTROPHIN; RELEASE; FACTOR; POLY; PEPTIDE; ANALOGUE; USEFUL; REGULATE; SECRETION; ACTH; LOWER; BLOOD; PRESSURE

#### **Class Codes**

International Classification (Main): C07K-014/695, C07K-007/10  
(Additional/Secondary): A61K-035/30, A61K-037/00, A61K-037/02, A61K-037/24, A61K-038/16, C07C-103/52, C07K-007/38, C07K-099/00, C12N-015/00, G01N-001/00

US Classification, Issued: 436086000, 424002000, 514012000, 530324000, 930DIG, 930DIG, 930010000, 930020000, 930021000

File Segment: CPI; EPI

DWPI Class: B04; S03

Manual Codes (EPI/S-X): S03-E13

Manual Codes (CPI/A-M): B04-B04J; B04-C01; B12-E01; B12-F05; B12-G04; B12-J01; B12-K04

**17/5/114 (Item 113 from file: 350)**

DIALOG(R)File 350:Derwent WPIX

(c) 2006 The Thomson Corporation. All rts. reserv.

0001044771

WPI ACC NO: 1976-05437X/

**3-Oxa-phenyl substituted prostaglandins - hypotensives, pressor agents, smooth muscle stimulants etc.**

Patent Assignee: UPJOHN CO (UPJO)

Inventor: BUNDY G L

**Patent Family** (1 patents, 1 countries)

Patent			Application			Update
Number	Kind	Date	Number	Kind	Date	
US 3931289	A	19760106	US 1970103338	A	19701231	197603 B
			US 1971185448	A	19710930	
			US 1974459759	A	19740411	
			US 1975625179	A	19751023	
			US 1975625180	A	19751023	
			US 1975625243	A	19751023	
			US 1974459759	A	19740411	

Priority Applications (no., kind, date): US 1974459759 A 19740411

**Alerting Abstract US A**

Prostaglandins in the formula (I) and their lower alkanooate esters and salts when R1=H are novel:- R1 = H, (1-8C)alkyl, (3-10C)cycloalkyl, (7-12 C)aralkyl, phenyl opt. substd. by 1, 2 or 3 chloro or (1-4C)alkyl or ethyl beta-substd. by 3-Cl, 2 or 3 Br or 1,2 or 3 I; R2,R3, R4,R5 and R6=H or (1-4C)alkyl, -CnH2n-=(1-10C)alkylene with 1-5C between -CHR2- and -O-; -CtH2t=bond or (1-10C)alkylene opt. substd. by 1 or 2 F and with 1-7C between -CR3OH- and the ring; T=(1-4C)alkyl, F, Cl, CF3 or OR9; R9=H, (1-4C)alkyl or tetrahydropyranyl; s=1, 2 or 3 with the proviso no more than two T are other than alkyl; CpH2p=(1-8C)alkylene with 1,2 or 3 C atoms between -CH=CH- or C C- and -O-; Z3=-CR5R6-). (I) are hypotensives, pressor agents, smooth muscle stimulants, antilipolytics, **gastric** secretion **inhibitors**, **blood** platelet aggregation **inhibitors**, epidermal proliferation stimulants, nasal decongestants, ulcer healing accelerators, oxytocin, potentiators, atonic uterine bleeding inhibitors, labour inducers and mammalian reproductive cycle regulants.

**Title Terms/Index Terms/Additional Words:** OXA; PHENYL; SUBSTITUTE;  
HYPOTENSIVE; PRESSOR; AGENT; SMOOTH; MUSCLE; STIMULATING

**Class Codes**

(Additional/Secondary): C07C-005/22, C07C-069/76  
US Classification, Issued: 560053000, 514822000, 514925000, 549415000,  
549422000, 549454000, 554217000, 556441000, 558046000, 560118000,  
560121000, 562462000, 562463000, 562470000, 562503000, 568649000

File Segment: CPI

DWPI Class: B03; B05

Manual Codes (CPI/A-M): B04-B02E; B12-A07; B12-C09; B12-E06; B12-E07;  
B12-E08; B12-E09; B12-F04; B12-F05; B12-G01; B12-H02; B12-H03; B12-J02;  
B12-K05; B12-L04